國家衛生研究院 NHRI:Item 3990099045/10278
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12500/13673 (91%)
造访人次 : 2577624      在线人数 : 539
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10278


    题名: Effect of mTOR inhibitors on the risk of cancer development after kidney transplantation in Chinese population
    作者: Kao, CC;Liu, JS;Lin, MH;Chang, FC;Lin, YC;Chen, HH;Chen, TW;Hsu, CC;Wu, MS
    贡献者: Division of Health Services and Preventive Medicine;Division of Geriatric Research
    摘要: Introduction The mTOR inhibitor is an immunosuppressive drug used in kidney transplantation. Whether the mTOR inhibitors is associated with reduced risk of cancer development in Chinese population is unknown. Methods We conducted a nationwide population-based study. Patients who did not have malignancy history and received kidney transplantation between 2000-2013 were enrolled. A total of 3628 patients were included. We conducted a propensity score matching to determine 793 recipients who had mTOR inhibitors > 30 days as the study group; 2835 recipients who did not have mTOR inhibitors as the control group. We calculated the cumulative tablets of Sirolimus (Rapamune ® 1mg, Pfizer) or Everolimus (Certican ® 0.5mg, Novartis) within the first year of kidney transplantation. The primary outcome is the development of cancer after kidney transplantation. A Cox proportional hazard model was applied to investigate the risk of cancer development. Results Among the 78-month median duration of observation, patients who received mTOR inhibitors were not associated with lower risk of cancer development. (Adjusted HR 0.94, 95% CI 0.75-1.16, P=0.74) We found patients who had lower doses of mTOR inhibitors (<330 tablets within the first year of kidney transplantation) were associated with higher risk of cancer development (HR 1.38, 95% CI 1.06-1.78, P=0.02); but higher doses of mTOR inhibitors did not carry a lower risk of cancer development. (HR 1.13, 95% CI 0.84-1.52, P=0.43). Conclusions The mTOR inhibitors was not associated with reduced risk of cancer development in kidney transplantation recipients in Chinese population. Lower doses of mTOR inhibitors within the first year of kidney transplantation may carry a worse outcome.
    日期: 2016-06
    關聯: American Journal of Transplantation. 2016 Jun;16(Suppl. 3):227.
    Link to: http://dx.doi.org/10.1111/ajt.13897
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1600-6135&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000383373902062
    显示于类别:[許志成] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000383373902062.pdf280KbAdobe PDF436检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈